This is a competing renewal application for five years of funding of a P60 Comprehensive Center with the theme of improving treatment of substance abuse. Originally the Center focused on heroin, but later expanded to include cocaine, nicotine and alcohol. The Center traces its origin to the Philadelphia VA Substance Abuse Program founded in 1971 with the intent of integrating research and treatment. The first NIH and VA grants were obtained in 1973-74 and additional investigators and related lines of research were gradually added. In 1987, NIDA center funding was obtained and a clinical research treatment program for non-veterans was founded on the Penn campus. The P60 NIDA Center now forms the umbrella for multiple NIDA, NIAID, NIAAA and VA research programs located in the Penn site as well as the VA and the nearby Presbyterian Medical Center campus of the University. An important outgrowth of the Center in 1991 was the Treatment Research Institute (TRI), a non-profit organization dedicated to technology transfer and analysis of individual substance abuse treatment programs throughout the country. While the Center has always emphasized clinical research, it has maintained some basic research activity utilizing animal models of substance abuse to screen potential medications for substance use disorders. There is an emphasis on interaction between pre-clinical and clinical investigators both among our faculty and our external advisory board. The Center also houses an extensive education program on the subject of substance abuse directed at medical students, residents, post-doctoral fellows and drug abuse counselors. This program is not limited to the University of Pennsylvania, but rather is a national resource as a Center of Excellence for the VA and for the nationwide minority fellowship program it operates. Dissemination of new technology to the treatment community has always been an important goal of the Center. This has recently been facilitated by our designation as a node in the Clinical Trials Network. In addition, the TRI has begun a national treatment monitoring initiative that will ultimately include 700 treatment programs across the country.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Comprehensive Center (P60)
Project #
3P60DA005186-17S1
Application #
6804909
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Czechowicz, Dorynne D
Project Start
1992-09-30
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
17
Fiscal Year
2003
Total Cost
$84,000
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Franklin, Teresa R; Jagannathan, Kanchana; Hager, Nathan et al. (2018) Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. Drug Alcohol Depend 182:78-85
Wetherill, Reagan R; Jagannathan, Kanchana; Hager, Nathan et al. (2016) Influence of menstrual cycle phase on resting-state functional connectivity in naturally cycling, cigarette-dependent women. Biol Sex Differ 7:24
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Van Horn, Deborah H A; Drapkin, Michelle; Lynch, Kevin G et al. (2015) Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment. Addict Res Theory 23:391-403
Franklin, Teresa R; Jagannathan, Kanchana; Wetherill, Reagan R et al. (2015) Influence of menstrual cycle phase on neural and craving responses to appetitive smoking cues in naturally cycling females. Nicotine Tob Res 17:390-7
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Goldman, Marina; Ehrman, Ronald N; Suh, Jesse J et al. (2015) Brief report: ""spiders-No, puppies-Go"", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. J Adolesc 38:45-8
McKay, James R; Drapkin, Michelle L; Van Horn, Deborah H A et al. (2015) Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol and cocaine dependence. J Consult Clin Psychol 83:1021-32
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N et al. (2014) The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 78:33-9

Showing the most recent 10 out of 111 publications